Latest Us Market News

4DMedical has landed a three-year commercial contract with SimonMed Imaging, deploying its CT:VQ™ technology across more than 170 US outpatient centres, marking a significant step in its US market expansion.

Bubs Australia expects FY26 revenue between $105 million and $115 million, with underlying EBITDA forecast at $4 million to $8 million despite external challenges including regulatory delays and increased air freight costs.

Volt Group reported an 8% revenue decline in FY25 amid strategic shifts but is poised for growth with the 4D Delta acquisition driving a 150% revenue surge in Q1 FY26.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

Australian Vintage Limited has locked in a $128 million refinancing deal extending to 2029 and reported a significant cash flow turnaround in FY26, driven by innovation and strategic acquisitions.

HighCom Limited has locked in a $4.5 million loan facility with Commonwealth Bank, replacing its US debt and complementing a recent $7.8 million capital raise to fuel working capital and sales expansion.

Adveritas Limited’s annualised recurring revenue (ARR) has surged to $16.3 million, driven by rapid organic growth of its SME self-serve platform and expanding North American footprint beyond gaming.

Energy Transition Minerals (ASX: ETM) has appointed Alexander B. Gray, a former senior US national security official, to its Strategic Advisory Board, enhancing its geopolitical clout and US engagement as it pushes forward with its Greenland rare earths project.

Pacific Edge reported a steep 47% revenue drop in FY26 following Medicare coverage loss but secured a draft Medicare policy covering its Cxbladder tests and raised NZ$25.4 million to fuel growth and commercial execution.

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

Guzman y Gomez has abruptly exited the US market, citing financial underperformance despite brand progress, while reaffirming strong Australian growth and international franchise confidence.

Vitrafy Life Sciences has achieved a major validation milestone with US Army-backed Phase II results showing its no-wash platelet cryopreservation protocol delivers 94% post-thaw recovery, outperforming existing standards and advancing FDA registration plans.